Drug Profile

UCART CS1

Alternative Names: UCART-CS1; UCART-CS1A

Latest Information Update: 10 May 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Cellectis
Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase I Multiple myeloma

Most Recent Events

04 May 2023 UCART CS1 is still in phase-I trials for Multiple-myeloma (Second-line therapy or greater) is still ongoing in USA
04 May 2023 Cellectis terminates phase-I MELANI-01 trials for Multiple-myeloma (Second-line therapy or greater) in USA
28 Mar 2023 No recent reports of development identified for phase-I development in Multiple-myeloma(Second-line therapy or greater) in USA (Parenteral)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com